Stocklytics Platform
Asset logo for symbol VTGN
VistaGen Therapeutics
VTGN61
$2.40arrow_drop_down2.46%-$0.06
Penny Stock
Asset logo for symbol VTGN
VTGN61

$2.40

arrow_drop_down2.46%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

VistaGen Therapeutics (VTGN) Stocklytics Forecast

According to analysts, VistaGen Therapeutics Inc (VTGN) has the potential for significant growth in the coming years. With a unique approach to drug development and a strong pipeline of candidates, the company is well-positioned to capitalize on opportunities in the biotech industry. The current stock price of VTGN is seen as undervalued by many experts, making it an attractive investment option.
In terms of price predictions, several factors need to be considered. One important consideration is the company's ongoing clinical trials and the potential for positive results. If these trials are successful, it could lead to a significant increase in VTGN's stock price. Additionally, market trends and investor sentiment towards biotech companies can also impact the stock's performance.
add VistaGen Therapeutics to watchlist

Keep an eye on VistaGen Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for VistaGen Therapeutics (VTGN) stock?

Analysts have set a target price of $21.75 for VistaGen Therapeutics (VTGN), based on forecasts from 4 analysts. The predicted price range extends from a high of $30 to a low of $12. This represents a potential increase of up to 1.15K% and a decrease of 400% from the current price of $2.4. These forecasts are as of 2018 May 24.
help

What are the analyst ratings for VistaGen Therapeutics (VTGN) stock?

The analyst ratings for VistaGen Therapeutics (VTGN) are distributed as follows: 5 analysts recommend buying, 0 have a neutral stance, and 0 suggest selling. There is a split consensus, with equal support for two of the rating categories. These ratings indicate the general sentiment among the analysts covering VistaGen Therapeutics .
help

What is the AI price prediction for VistaGen Therapeutics (VTGN) stock?

At present, there is no AI or machine-learning-based price prediction available for VistaGen Therapeutics (VTGN) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level